Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.37 |
| ▸ | YAP1 | P46937 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491443 | 0.89 | ITGB3 (0.48) | ITGB3ITGA2B | |
| SCHEMBL1491583 | 0.75 | HDAC1 (0.56) | CTSLITGB3ITGA2BHDAC1HDAC6 | |
| SCHEMBL12660767 | 0.71 | HDAC1 (0.46) | CTSLITGB3ITGA2BYAP1HDAC1 | |
| SCHEMBL12672779 | 0.67 | HDAC1 (0.43) | CTSLITGB3ITGA2BHDAC1HDAC6 | |
| SCHEMBL23643095 | 0.66 | CTSL (0.53) | CTSLEPHX2MEN1ALDH1A1KMT2A | |
| SCHEMBL25769241 | 0.66 | CTSL (0.53) | CTSLEPHX2MEN1ALDH1A1KMT2A | |
| SCHEMBL25769231 | 0.66 | CTSL (0.53) | CTSLEPHX2MEN1ALDH1A1KMT2A | |
| SCHEMBL31723024 | 0.65 | GRIA1 (0.50) | CTSLITGB3ITGA2BYAP1ALDH1A1 | |
| SCHEMBL25769206 | 0.64 | PSEN1 (0.51) | CTSLEPHX2KDM4EALDH1A1 | |
| SCHEMBL23642933 | 0.64 | PSEN1 (0.51) | CTSLEPHX2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-1879895-A1 | ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | CTSL 2032/4885ITGB3 2878/4885ITGA2B 2142/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | CTSL 848/4885ITGB3 1221/4885ITGA2B 2369/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | CTSL 2209/4885ITGB3 968/4885ITGA2B 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.